All Trials

Vonescimab for the Treatment of Previously Treated Advanced or Unresectable Leiomyosarcoma - a Phase II Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic leiomyosarcoma, ECOG 0–2, measurable disease, and 1–3 prior systemic therapy lines are treated with single-agent IV ivonescimab every 3 weeks for up to 24 months. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, combining checkpoint blockade with anti-angiogenic activity; patients with prior PD-1/PD-L1 or VEGF-targeted therapy are excluded.

ClinicalTrials.gov ID: NCT07516925

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adults with measurable advanced/metastatic undifferentiated pleomorphic sarcoma, myxofibrosarcoma, high-grade pleomorphic sarcoma, or high-grade undifferentiated sarcoma, ECOG 0–2, without prior checkpoint inhibitor therapy. Treatment is zanzalintinib (XL092), an oral multikinase inhibitor targeting VEGFR2, MET, and TAM kinases (TYRO3/AXL/MER), plus pembrolizumab anti–PD-1 immunotherapy.

ClinicalTrials.gov ID: NCT07283731

DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Randomized first-line trial for adults with untreated extensive-stage SCLC, ECOG 0–1, with tumor tissue available for DLL3 testing; stable treated or untreated brain metastases may be allowed. Patients receive atezolizumab/carboplatin/etoposide with or without obrixtamig, an IV DLL3×CD3 bispecific T-cell engager that redirects T cells against DLL3-expressing tumor cells.

ClinicalTrials.gov ID: NCT07472517

A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable WHO grade 1–3 meningioma progressing within 6 months despite, or not amenable to, standard local therapy receive oral once-daily zanzalintinib monotherapy. Zanzalintinib (XL092) is an investigational multitargeted tyrosine kinase inhibitor of VEGFR2, MET, and TAM kinases TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT07428616

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated ER-positive, HER2-negative unresectable locoregionally recurrent or metastatic breast cancer and ECOG 0–1 receive first-line camizestrant, an oral selective estrogen receptor degrader, plus the CDK4/6 inhibitor ribociclib. Pre/perimenopausal women and men without prior orchiectomy also receive ovarian or testicular suppression.

ClinicalTrials.gov ID: NCT07647328

An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with refractory, c-Met–overexpressing metastatic colorectal cancer are randomized to telisotuzumab adizutecan, a c-Met–targeted antibody-drug conjugate delivering a topoisomerase I inhibitor, plus bevacizumab versus trifluridine/tipiracil (LONSURF) plus bevacizumab.

ClinicalTrials.gov ID: NCT07525206

A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with unresectable stage IV clear-cell RCC recurring during or within 24 months after adjuvant anti-PD-1/L1 therapy, with no other prior systemic RCC treatment, are randomized to belzutifan (HIF-2α inhibitor) plus zanzalintinib (VEGFR2/MET/TYRO3/AXL/MER inhibitor) or cabozantinib.

ClinicalTrials.gov ID: NCT07227402

A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable or metastatic HCC, Child-Pugh A and ECOG 0–1, whose disease progressed after exactly one anti-PD-(L)1–containing systemic regimen receive lenvatinib plus either visugromab and nivolumab or placebo. Visugromab is an anti-GDF-15 antibody intended to restore T-cell tumor infiltration and overcome checkpoint-inhibitor resistance; nivolumab inhibits PD-1.

ClinicalTrials.gov ID: NCT07219459

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated stage IV squamous or non-squamous NSCLC, ECOG 0–1, and no actionable alteration with an approved first-line targeted therapy receive pembrolizumab plus histology-appropriate platinum chemotherapy. Patients are randomized to IV EIK1001, a dual TLR7/8 agonist that activates dendritic cells to promote antitumor immunity, or placebo.

ClinicalTrials.gov ID: NCT07365319

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Women with cyclin E1 protein–positive, platinum-resistant but not primarily platinum-refractory high-grade serous ovarian, primary peritoneal, or fallopian tube cancer and ECOG 0–1 are randomized to oral azenosertib or investigator-selected chemotherapy. Azenosertib is a selective WEE1 kinase inhibitor that disrupts G2/M checkpoint control, increasing replication stress and DNA damage.

ClinicalTrials.gov ID: NCT07546500